These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 26179124)

  • 1. Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): A randomized, controlled trial.
    Benatar M; Mcdermott MP; Sanders DB; Wolfe GI; Barohn RJ; Nowak RJ; Hehir M; Juel V; Katzberg H; Tawil R;
    Muscle Nerve; 2016 Mar; 53(3):363-9. PubMed ID: 26179124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design of the efficacy of prednisone in the treatment of ocular myasthenia (EPITOME) trial.
    Benatar M; Sanders DB; Wolfe GI; McDermott MP; Tawil R
    Ann N Y Acad Sci; 2012 Dec; 1275():17-22. PubMed ID: 23278573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of prednisone on the progression from ocular to generalized myasthenia gravis.
    Monsul NT; Patwa HS; Knorr AM; Lesser RL; Goldstein JM
    J Neurol Sci; 2004 Feb; 217(2):131-3. PubMed ID: 14706214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment.
    Kupersmith MJ; Ying G
    Br J Ophthalmol; 2005 Oct; 89(10):1330-4. PubMed ID: 16170126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of generalized disease at 2 years in patients with ocular myasthenia gravis.
    Kupersmith MJ; Latkany R; Homel P
    Arch Neurol; 2003 Feb; 60(2):243-8. PubMed ID: 12580710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pediatric Autoimmune Ocular Myasthenia Gravis: Evaluation of Presentation and Treatment Outcomes in a Large Cohort.
    Fisher KS; Gill J; Todd HF; Yang MB; Lopez MA; Abid F; Lotze T; Shah VS
    Pediatr Neurol; 2021 May; 118():12-19. PubMed ID: 33684630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cigarette Smoking and Activities of Daily Living in Ocular Myasthenia Gravis.
    Gratton SM; Herro AM; Feuer WJ; Lam BL
    J Neuroophthalmol; 2016 Mar; 36(1):37-40. PubMed ID: 26457691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Childhood myasthenia gravis: clinical features and outcomes.
    Sri-udomkajorn S; Panichai P; Liumsuwan S
    J Med Assoc Thai; 2011 Aug; 94 Suppl 3():S152-7. PubMed ID: 22043769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Analysis for the effect of different regimens on ocular myasthenia gravis in children].
    Liu C; Wang X; Xie L; Peng J; Wu L; Zheng X
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Nov; 42(11):1275-1279. PubMed ID: 29187654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Ocular myasthenia: clinical course and strategies for treatment].
    Marzo ME; Pérez López-Fraile I; Capablo JL; Ara JR; Usón M
    Rev Neurol; 1998 Mar; 26(151):398-400. PubMed ID: 9585951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The natural history and ophthalmic involvement in childhood myasthenia gravis at the hospital for sick children.
    Mullaney P; Vajsar J; Smith R; Buncic JR
    Ophthalmology; 2000 Mar; 107(3):504-10. PubMed ID: 10711889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of use of pyridostigmine and requirement of vecuronium in patients with myasthenia gravis.
    Tripathi M; Kaushik S; Dubey P
    J Postgrad Med; 2003; 49(4):311-4; discussion 314-5. PubMed ID: 14699228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ocular myasthenia gravis - How effective is low dose prednisone long term?
    Verma R; Wolfe GI; Kupersmith MJ
    J Neurol Sci; 2021 Jan; 420():117274. PubMed ID: 33360170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis.
    Pasnoor M; He J; Herbelin L; Burns TM; Nations S; Bril V; Wang AK; Elsheikh BH; Kissel JT; Saperstein D; Shaibani JA; Jackson C; Swenson A; Howard JF; Goyal N; David W; Wicklund M; Pulley M; Becker M; Mozaffar T; Benatar M; Pazcuzzi R; Simpson E; Rosenfeld J; Dimachkie MM; Statland JM; Barohn RJ;
    Neurology; 2016 Jul; 87(1):57-64. PubMed ID: 27306628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis.
    De Feo LG; Schottlender J; Martelli NA; Molfino NA
    Muscle Nerve; 2002 Jul; 26(1):31-6. PubMed ID: 12115946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up.
    Kupersmith MJ
    J Neurol; 2009 Aug; 256(8):1314-20. PubMed ID: 19377863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myasthenia gravis in Jamaican children: a 12-year institutional review.
    Melbourne Chambers R; Forrester S; Gray R; Tapper J; Trotman H
    Paediatr Int Child Health; 2012 Feb; 32(1):47-50. PubMed ID: 22525448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors associated with insensitivity to pyridostigmine therapy in Thai patients with ocular myasthenia gravis.
    Chirapapaisan N; Tanormrod S; Chuenkongkaew W
    Asian Pac J Allergy Immunol; 2007 Mar; 25(1):13-6. PubMed ID: 17891917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Celebrating the 70 years of pyridostigmine on therapy of Myasthenia Gravis: historical aspects of the preliminary trials.
    Lorenzoni PJ; Kay CSK; Ducci RD; Fustes OJH; Werneck LC; Scola RH
    Arq Neuropsiquiatr; 2020 Mar; 78(3):179-181. PubMed ID: 32215460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myasthenia gravis: an unusual cause of diplopia in polymyalgia rheumatica.
    Fernández-Castro M; Andreu JL; Muñoz P; Ornilla E
    Clin Exp Rheumatol; 2004; 22(4):505. PubMed ID: 15301257
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.